Literature DB >> 15292284

Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation.

Bryan R Haugen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15292284     DOI： 10.1210/jc.2004-0920

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  3 in total

Review 1.  Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.

Authors:  Kenneth B Ain
Journal:  Endocrine       Date:  2015-06-25       Impact factor: 3.633

Review 2.  Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.

Authors:  Chao Ma; Jiawei Xie; Wanxia Liu; Guoming Wang; Shuyao Zuo; Xufu Wang; Fengyu Wu
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

3.  MnTnBuOE-2-PyP treatment protects from radioactive iodine (I-131) treatment-related side effects in thyroid cancer.

Authors:  Anery Patel; Elizabeth A Kosmacek; Kurt W Fisher; Whitney Goldner; Rebecca E Oberley-Deegan
Journal:  Radiat Environ Biophys       Date:  2019-11-14       Impact factor: 1.925
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.